LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 791

Search options

  1. Article ; Online: Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    Powles, T

    Annals of oncology : official journal of the European Society for Medical Oncology

    2020  Volume 32, Issue 3, Page(s) 422–423

    MeSH term(s) Humans ; Anilides ; Carcinoma, Renal Cell/diagnosis ; Carcinoma, Renal Cell/drug therapy ; Follow-Up Studies ; Kidney Neoplasms/diagnosis ; Kidney Neoplasms/drug therapy ; Nivolumab/therapeutic use ; Pyridines
    Chemical Substances Anilides ; cabozantinib (1C39JW444G) ; Nivolumab (31YO63LBSN) ; Pyridines
    Language English
    Publishing date 2020-11-30
    Publishing country England
    Document type Letter
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1016/j.annonc.2020.11.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer.

    Powles, Thomas

    European urology

    2020  Volume 77, Issue 4, Page(s) 454–456

    MeSH term(s) Carcinoma, Renal Cell ; Humans ; Ipilimumab ; Kidney Neoplasms ; Nivolumab ; Risk Factors
    Chemical Substances Ipilimumab ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2020-01-28
    Publishing country Switzerland
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2020.01.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Where next in kidney cancer?

    Powles, T

    Annals of oncology : official journal of the European Society for Medical Oncology

    2016  Volume 27, Issue 8, Page(s) 1376–1377

    MeSH term(s) Humans ; Kidney Neoplasms
    Language English
    Publishing date 2016-07-25
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdw247
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Patient and Healthcare Professional Perspectives from ESMO 2022 on Bladder and Kidney Cancer: A Podcast.

    Filicevas, Alex / Powles, Thomas

    Oncology and therapy

    2023  Volume 11, Issue 3, Page(s) 277–289

    Abstract: In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress are discussed for a second year in a row, from the perspective of both a patient advocate and a healthcare professional. The patient advocacy track ... ...

    Abstract In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress are discussed for a second year in a row, from the perspective of both a patient advocate and a healthcare professional. The patient advocacy track at the congress included two patient-focused sessions each day on a variety of topics. Here, the authors discuss the importance of involving patients in the design of clinical trials, as well as strategies to improve dialogue and connections between clinicians, researchers and patients. Patient advocacy organisations provide essential services to patients with cancer and their caregivers, and patient advocates play a critical role in helping to inform patients and caregivers in making clinical decisions. Congresses such as ESMO provide an important platform for patient advocates to connect with each other and with physicians and researchers to ensure that patients are placed at the centre of the conversation and are up to date on the latest findings that affect them. The authors also discuss the latest research on genitourinary cancers, focusing on bladder and kidney cancer. Promising results are emerging for combination antibody-drug conjugates and immunotherapy for patients with hard-to-treat, locally advanced or metastatic bladder cancer who are ineligible for platinum-based chemotherapy. In the management of kidney cancer, we may be reaching an end for immune checkpoint inhibitors on their own; the path ahead will be to find new targets and combinations. Podcast Audio (MP4 169766 KB).
    Language English
    Publishing date 2023-06-06
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2848647-X
    ISSN 2366-1089 ; 2366-1070
    ISSN (online) 2366-1089
    ISSN 2366-1070
    DOI 10.1007/s40487-023-00231-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: O2.2PDL1 blockade in metastatic bladder cancer.

    Powles, T

    Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

    2015  Volume 26 Suppl 2, Page(s) ii2

    Abstract: The outcome of patients with urothelial bladder cancer is poor. No new treatment have been introduced into the clinic for a generation. Recent data has demonstrated significant activity of immune checkpoint inhibitors in heavily pretreated metastatic ... ...

    Abstract The outcome of patients with urothelial bladder cancer is poor. No new treatment have been introduced into the clinic for a generation. Recent data has demonstrated significant activity of immune checkpoint inhibitors in heavily pretreated metastatic disease. Activity was particularly marked in tumors which over express PD-L1. The drugs appear well tolerated and responses were long lasting. This has resulted in a number of potentially practice changing studies which are ongoing and breakthrough FDA designation for MPDL3280A. Prominent questions for the future include1) better defining patients who benefit from therapy, 2) the role of combinations of therapy and 3) the optimal clinical space for drug development.
    Language English
    Publishing date 2015-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdv080.2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma.

    Powles, Tom

    European urology

    2018  Volume 74, Issue 5, Page(s) 679–680

    MeSH term(s) Antibodies, Monoclonal ; Carcinoma, Renal Cell ; Humans ; Ipilimumab ; Kidney Neoplasms ; Nivolumab ; Sunitinib
    Chemical Substances Antibodies, Monoclonal ; Ipilimumab ; Nivolumab (31YO63LBSN) ; Sunitinib (V99T50803M)
    Language English
    Publishing date 2018-08-10
    Publishing country Switzerland
    Document type Journal Article ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2018.07.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Choosing Front-line Treatment for Metastatic Renal Cancer: Which Data Are Meaningful?

    Powles, Tom

    European urology

    2018  Volume 74, Issue 3, Page(s) 322–323

    MeSH term(s) Carcinoma, Renal Cell ; Humans ; Kidney Neoplasms ; Molecular Targeted Therapy ; Network Meta-Analysis
    Language English
    Publishing date 2018-05-23
    Publishing country Switzerland
    Document type Editorial ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2018.05.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers.

    Vogl, Ursula Maria / McDermott, David / Powles, Thomas

    Lancet (London, England)

    2023  Volume 401, Issue 10379, Page(s) 796–798

    MeSH term(s) Humans ; Nivolumab ; Carcinoma, Renal Cell/drug therapy ; Ipilimumab ; Kidney Neoplasms/drug therapy ; Sunitinib/therapeutic use ; Adjuvants, Immunologic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols
    Chemical Substances Nivolumab (31YO63LBSN) ; Ipilimumab ; Sunitinib (V99T50803M) ; Adjuvants, Immunologic
    Language English
    Publishing date 2023-02-09
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(22)02631-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Clinical Trials Corner.

    Powles, Thomas

    Kidney cancer (Clifton, Va.)

    2017  Volume 1, Issue 1, Page(s) 89–91

    Language English
    Publishing date 2017-07-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2961890-3
    ISSN 2468-4570 ; 2468-4562
    ISSN (online) 2468-4570
    ISSN 2468-4562
    DOI 10.3233/KCA-179002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology.

    Powles, Thomas

    Future oncology (London, England)

    2017  Volume 13, Issue 18, Page(s) 1581–1583

    Abstract: Thomas Powles speaks to Sebastian Dennis-Beron, Commissioning Editor: Dr. Thomas Powles is a clinical professor of genitourinary oncology and the lead for solid tumor research at Barts Cancer Institute in London. His main research interests are in ... ...

    Abstract Thomas Powles speaks to Sebastian Dennis-Beron, Commissioning Editor: Dr. Thomas Powles is a clinical professor of genitourinary oncology and the lead for solid tumor research at Barts Cancer Institute in London. His main research interests are in genital and urinary cancers, in which he leads a spectrum of clinical studies from Phase I to randomized Phase III investigating novel targeted and immune therapies. His research also focuses on correlation of novel biomarkers and aims to define markers with prognostic value that may predict response or resistance to therapy. Dr. Powles is the author of more than 100 publications, on the editorial board of a number of journals, and part of the faculty for multiple global oncology meetings. He qualified from St Bartholomew's Medical School and received his MD from the University of London.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Combined Modality Therapy ; Humans ; Immunotherapy ; Medical Oncology ; Molecular Targeted Therapy ; Treatment Outcome ; Urologic Neoplasms/immunology ; Urologic Neoplasms/metabolism ; Urologic Neoplasms/mortality ; Urologic Neoplasms/therapy
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents, Immunological ; Biomarkers, Tumor ; durvalumab (28X28X9OKV)
    Language English
    Publishing date 2017-07-20
    Publishing country England
    Document type Interview
    ZDB-ID 2184533-5
    ISSN 1744-8301 ; 1479-6694
    ISSN (online) 1744-8301
    ISSN 1479-6694
    DOI 10.2217/fon-2017-0207
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top